Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 160

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 160
---
31, 2023, and is part of our cooperation agreement with SciSparc. The invention disclosed therein is directed to the methods for treating cocaine addiction by administering a therapeutically effective amount of MEAI and the methods of treatment comprise administering MEAI in combination with N-acylethanolamines, for example, PEA. MEAI for the Treatment of Metabolic Syndrome patent family was filed jointly with Yissum, on September 20, 2023. The invention disclosed therein is directed to the methods for treating metabolic syndrome by administering a therapeutically effective amount of MEAI and methods comprising administering MEAI in combination with N-acylethanolamines, for example, PEA. Compositions comprising 3MMC and n-acylethanolamines and methods for treating dyskinesias such as tardive dyskinesia is a patent family filed on July 27, 2023, as part of our cooperation agreement with SciSparc. The invention disclosed therein is directed to compositions and methods for potentiating therapeutic effects and/or reducing side-effects of 3MMC. The present invention provides pharmaceutical compositions comprising 3MMC and N-acylethanolamines, for example, Palmitoylethanolamide, or PEA, and methods for their use in treating dyskinesias such as tardive dyskinesia. Compositions comprising 3,4-METHYLENEDIOXYMETHAMPHETAMINE and n-acylethanolamines and uses thereof is a patent family filed on February 15, 2023, as part of our cooperation agreement with SciSparc. The invention disclosed therein is directed to the compositions and methods for potentiating therapeutic effects and/or reducing side-effects of 3,4-METHYLENEDIOXYMETHAMPHETAMINE. The present disclosure encompasses compositions and methods for potentiating therapeutic effects and/or reducing side-effects of 3,4-methylenedioxymethamphetamine (MDMA). The disclosure provides pharmaceutical compositions and combinations comprising MDMA and N-acylethanolamines, for example, Palmitoylethanolamide (“PEA”) and methods for their use in a variety of indications amenable to treatment, including, but not limited to post-traumatic stress disorder (PTSD), anxiety, and eating disorders. Compositions comprising LYSERGIC ACID DIETHYLAMIDE and N-acylethanolamines and uses thereof is a patent family filed on February 10